Selection of Publications

Battistella M, Wilson JA, Abbaticchio A, Gee P, Hall R. Deprescribing in chronic kidney disease: An essential component of comprehensive medication management. Am J Health-Systems Pharmacists 2025; zxaf051. https://doi.org/10.1093/ajhp/zxaf051

Morris J, Battistella M, Tennankore K, Soroka S, Kendell C, Poyah P, More K, Grandy M, Ransom T, Kennie-Kaulbach N, Rainkie D, Tran J, Abidi SSR, Abidi S, Fulford N, Neville H, Naylor H, Woodill L, Bishop A, Rodrigues G, Harpell D, Stewart M, Wilson JA. Optimizing prescribing for individuals with type 2 diabetes and chronic kidney disease through the development and validation of algorithms for community pharmacists. Can J Kidney Health Dis. 2025 Jan 20; 12:20543581241309974. doi: 10.1177/20543581241309974

Wilson JA, Ratajczak N, Halliday K, Battistella M, Naylor H, Sheffield M, Judith M, Pitman J, Kennie-Kaulbach, Trenaman S, Gillis L. Medications for community pharmacists to dose adjust or avoid to enhance prescribing safety in individuals with advanced chronic kidney disease: a scoping review and modified Delphi. BMC Nephrol. 2024;25(1):386. doi:10.1186/s12882-024-03829-y

Saini R, More K, Wilson J, Clarke D, Vinson A, Tennankore K. Prescribing Practices of Erythropoiesis-Stimulating Agents in Dialysis-Dependent and Nondialysis-Dependent CKD: TH-PO883. J Am Soc Nephrol 2024; 35(10S): doi: 10.1681/ASN.2024vh6k25bn

Wilson JA, Pitman J, Marin J, Wazny LD, Battistella M. Review of the top nephrology studies of 2020-2023. Canadian Pharmacists Journal/Revue des Pharmaciens du Canada. 2024;0(0). doi:10.1177/17151635241250028

Wilson JA, Barkhouse N, Sheffield M, Laffin B, Bryne S, Seo L, MacIsaac S, Singh S, Tennankore K, Poyah P. 439 Development of a dosing tool of high-risk medications to support clinicians conducting ambulatory medication reconciliation in individuals with advanced chronic kidney disease: A quality improvement project. Am J Kid Dis. 2024; 83 (4): S135.

Tran J, Shaffelburg C, Phelan E, Neville H, Lively A, Tennankore K, More K, Poyah P, Soroka S, Harpell D, Wilson J. Community pharmacists’ perspectives of enablers and barriers to kidney function assessment and dose adjustment in advanced chronic kidney disease: A qualitative study using the theoretical domains framework. Can Pharm J / Revue des Pharmaciens du Canada. 2023;156(5):272-281. doi:10.1177/17151635231176530

Wilson J, Tran J, Shaffelburg C, Phelan E, Neville H, Lively A, Tennankore K, More K, Poyah P, Soroka S, Harpell D. Community pharmacists’ perspectives of enablers and barriers to kidney function assessment and dose adjustment in advanced chronic kidney disease: A qualitative study. Pharmacoepidemiol Drug Saf. 2023;32 Suppl 1:3-612. doi:10.1002/pds.5687

Cho T, Patrick N, Lefebvre, M, Desjarlais A, McCann D, Waldvogel B, Tonelli M, Garg A, Wilson J, Beaulieu M, Marin J, Orsulak C, Talson M, Sharma M, Feldberg J, Bohm C, Battistella, M. Development and validation of patient education tools for deprescribing in patients on hemodialysis. Can J Kidney Health and Dis 2023; 10:20543581221150676. doi: 10.1177/20543581221150676

England E, Sheffield M, Poyah P, Clark D, Wilson JA. Ferric derisomaltose evaluation in patients with non-dialysis dependent chronic kidney disease or peritoneal dialysis patients. Can J Hosp Pharm 2023;76(2):94-101. doi: 10.4212/cjhp.3310

Larivée NL, Michaud JB, More KM, Wilson JA, Tennankore KK. Hyperkalemia: Prevalence, Predictors and Emerging Treatments [published online ahead of print, 2022 Dec 12]. Cardiol Ther. 2023;12(1):35-63. doi: 10.1007/s40119-022-00289-z

Tran J, Harlow-Gillighan M, Taylor B, Wood M, Bartol C, West K, Soroka S, Wilson JA. A standardized approach for the post-operative management of hypocalcemia in dialysis patients with secondary hyperparathyroidism requiring parathyroidectomy. CANNT J 2022; 31(4): 11-17.

Lefebvre M, Ng P, Desjarlais A, McCann D, Waldvogel B, Tonelli M, Garg A, Wilson J, Beaulieu M, Marin J, Orsulak C, Lloyd A, McIntyre C, Feldberg J, Bohm C, Battistella M. Development, and validation of nine deprescribing algorithms for patients on hemodialysis to decrease polypharmacy. Can J of Kidney Health and Dis 2020; 7: 2054358120968674. doi: 10.1177/2054358120968674 

Kwofie MK, Wilson J. A potential risk from under-recognized perioperative anticoagulation from dalteparin used for extracorporeal circuit anticoagulation during hemodialysis. Can J Anaesth. 2019; 66(11):1419-1420. doi: 10.1007/s12630-019-01460-2

Wilson J, Tran J, Veith A, Landry D, Neville H, Kelly C, Soroka S, West K. Medication reimbursement model and cost savings in a Canadian ambulatory hemodialysis program. Can J Hosp Pharm 2019; 72(2): 155-9.

Soroka S, Agharazii M, Donnelly S, Roy L, Muirhead N, Cournoyer S, MacKinnon M, Pannu N, Barrett B, Madore F, Tennankore K, Wilson JA, Hilton F, Sherman N, Wolter K, Orazem J, Feugere G An adjustable dalteparin sodium dose regimen for the prevention of clotting in the extracorporeal circuit in hemodialysis: A clinical trial of safety and efficacy (the PARROT study). Can J of Kidney Health and Dis 2018; 5: 2054358118809104. doi: 10.1177/2054358118809104

Hemmelgarn B, Manns BJ, Soroka SD, Levin A, MacRae J, Tennankore K, Wilson JA, Weaver R, Ravani P, Quinn RR, Tonelli M, Kiaii M, Mossop P, Scott-Douglas NS. Effectiveness and cost of weekly recombinant tissue plasminogen activator hemodialysis catheter locking solution. Clin J Am Soc Nephrol. 2018; 13(3): 429-435. doi: 10.2215/CJN.08510817

Wilson J, Ladda M, Tran J, Wood M, Poyah P, Rodrigues G, Soroka S, Tennankore K. Ambulatory medication reconciliation in dialysis patients: Benefits and community practitioners’ perspectives. Can J Hosp Pharm 2017; 70(6): 443-449. doi: 10.4212/cjhp.v70i6.1719

Wilson J, Phillips M, Amany A, Wood M, Poyah P, Hiltz A, Carver H. An evaluation of ambulatory medication reconciliation in an outpatient Nephrology Clinic. CANNT J 2016; 26(2): 29-33.

Wilson JA, Mossop P, Tennankore K, Dipchand C, Drost S, Sheehy N, Soroka S. Comparison of an intensive versus standard hemodialysis central venous catheter dysfunction protocol: A quality assurance initiative. J Vasc Access 2016; 17(2): 143-150. doi: 10.5301/jva.5000501